Preliminary results of TATTON, a multi-arm phase Ib trial of AZD9291 combined with MEDI4736, AZD6094 or selumetinib in EGFR-mutant lung cancer.-Reference-Cited by-全球学者库

Preliminary results of TATTON, a multi-arm phase Ib trial of AZD9291 combined with MEDI4736, AZD6094 or selumetinib in EGFR-mutant lung cancer.

Published:2015-05-20 Issue:15_suppl Volume:33 Page:2509-2509
ISSN:0732-183X
Container-title:Journal of Clinical Oncology
language:en
Short-container-title:JCO

Author:

Oxnard Geoffrey R.¹,Ramalingam Suresh S.²,Ahn Myung-Ju³,Kim Sang-We⁴,Yu Helena Alexandra⁵,Saka Hideo⁶,Horn Leora⁷,Goto Koichi⁸,Ohe Yuichiro⁹,Cantarini Mireille¹⁰,Frewer Paul¹⁰,Lahn Michael¹⁰,Yang James Chih-Hsin¹¹

Affiliation:

1. Dana-Farber Cancer Institute, Boston, MA

2. The Winship Cancer Institute of Emory University, Atlanta, GA

3. Samsung Medical Center, Seoul, South Korea

4. Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea

5. Memorial Sloan Kettering Cancer Center, New York, NY

6. Nagoya Medical Center, Nagoya, Japan

7. Vanderbilt-Ingram Cancer Center, Nashville, TN

8. Division of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa, Chiba, Japan

9. National Cancer Center Hospital East, Kashiwa, Japan

10. AstraZeneca, Macclesfield, United Kingdom

11. Department of Oncology, National Taiwan University Hospital; Graduate Institute of Oncology & Cancer Research Center, National Taiwan University, Taipei, Taiwan

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

Link

http://ascopubs.org/doi/pdfdirect/10.1200/jco.2015.33.15_suppl.2509

Cited by 30 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. MET alterations and their impact on the future of non-small cell lung cancer (NSCLC) targeted therapies;Expert Opinion on Therapeutic Targets;2021-04-03

2. A phase Ib study of the highly selective MET-TKI savolitinib plus gefitinib in patients with EGFR-mutated, MET-amplified advanced non-small-cell lung cancer;Investigational New Drugs;2020-10-14

3. Overcoming Resistance to Drugs Targeting KRAS Mutation;The Innovation;2020-08

MET Oncogene in Non-Small Cell Lung Cancer: Mechanism of MET Dysregulation and Agents Targeting the HGF/c-Met Axis

;OncoTargets and Therapy;2020-03